A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers (S5.005)Irfan A. Qureshi,Vladimir Coric,Kimberly Gentile,Richard Larouche,Mario Tanguay,Robert M. BermanNeurology(2019)引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要